Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C-C motif chemokine 14 as diagnostic and prognostic biomarker assays in renal injuries.
1. A method for evaluating renal status in a subject that is diagnosed as having an acute kidney injury (AKI), wherein the subject meets the definition RIFLE I or F or KDIGO Stage 2 or 3, and treating the subject based on the evaluation, the method comprising:
(a) performing an assay configured to detect C-C motif chemokine 14 on a body fluid sample obtained from the subject to provide an assay result indicating a level of C-C motif chemokine 14 in the sample;
(b) determining that the subject is likely to respond favorably to diuretic treatment when the level of C-C motif chemokine 14 in the sample is below a predetermined threshold; and
(c) treating the subject having the level of C-C motif chemokine 14 below the predetermined threshold with diuretic therapy.
2. The method of claim 1 , wherein the body fluid is urine, blood, serum, or plasma.
3. The method of claim 2 , wherein said assay result is a measured urine concentration of C-C motif chemokine 14.
4. The method of claim 1 , wherein the subject is diagnosed as having an acute kidney injury meeting the definition RIFLE F or KDIGO Stage 3 at the time the time the body fluid sample is obtained.
5. A method for evaluating renal status in a subject and treating the subject based on the evaluation, comprising:
(a) selecting the subject for evaluation based on a measured value of one or more AKI biomarkers that exceeds a threshold indicative of an increased risk of having an acute kidney injury that meets the definition RIFLE I or F or KDIGO Stage 2 or 3;
(b) performing an assay configured to detect C-C motif chemokine 14 on a body fluid sample obtained from the subject to provide an assay result indicating a level of C-C motif chemokine 14 in the sample;
(c) determining that the subject is likely to respond favorably to diuretic treatment when the level of C-C motif chemokine 14 in the sample is below a predetermined threshold; and
(d) treating the subject having the level of C-C motif chemokine 14 below the predetermined threshold with diuretic therapy.
6. The method of claim 5 , wherein the AKI biomarkers are one or more of Insulin-like growth factor-binding protein 7, Metalloproteinase inhibitor 2, Neutrophil gelatinase-associated lipocalin, Cystatin-C, Interleukin-18, Hepatitis A virus cellular receptor 1, Glutathione S-transferase P, Creatinine, and Fatty acid-binding protein, liver, including combinations thereof.
7. The method of claim 5 , wherein the body fluid is urine, blood, serum, or plasma.
8. The method of claim 7 , wherein said assay result is a measured urine concentration of C-C motif chemokine 14.
9. The method of claim 5 , wherein the subject is diagnosed as having an acute kidney injury meeting the definition RIFLE F or KDIGO Stage 3 at the time the time the body fluid sample is obtained.
10. The method of claim 1 , wherein the assay result is a measured concentration of C-C motif chemokine 14.
11. The method of claim 1 , wherein the method further comprises contacting all or a portion of the body fluid sample with a binding reagent that specifically binds to C-C motif chemokine 14.
12. The method of claim 11 , wherein the binding reagent is an antibody.
13. The method of claim 1 , wherein the assay is an immunoassay.
14. The method of claim 13 , wherein the assay is a sandwich immunoassay.
15. The method of claim 1 , wherein the assay is a competitive binding assay.
16. The method of claim 5 , wherein the assay result is a measured concentration of C-C motif chemokine 14.
17. The method of claim 5 , wherein the method further comprises contacting all or a portion of the body fluid sample with a binding reagent that specifically binds to C-C motif chemokine 14.
18. The method of claim 17 , wherein the binding reagent is an antibody.
19. The method of claim 5 , wherein the assay is an immunoassay.
20. The method of claim 19 , wherein the assay is a sandwich immunoassay.
21. The method of claim 5 , wherein the assay is a competitive binding assay.